Kodiak Sciences Inc
Company Profile
Business description
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Contact
1250 Page Mill Road
Palo AltoCA94304
USAT: +1 650 281-0850
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
124
Stocks News & Analysis
stocks
What a wobby AI trade could mean for Anthropic's IPO
stocks
Investor Playbook: What Transurban, APA and Deterra have in common?
stocks
Our view after REA’s share price rally
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,150.00 | 5.30 | 0.06% |
| CAC 40 | 8,139.00 | 66.37 | -0.81% |
| DAX 40 | 25,820.36 | 504.65 | -1.92% |
| Dow JONES (US) | 51,285.73 | 237.33 | -0.46% |
| FTSE 100 | 10,673.94 | 108.72 | -1.01% |
| HKSE | 24,588.14 | 106.28 | 0.43% |
| NASDAQ | 24,579.43 | 264.43 | 1.09% |
| Nikkei 225 | 59,411.34 | 1,976.57 | 3.44% |
| NZX 50 Index | 13,969.25 | 29.25 | -0.21% |
| S&P 500 | 7,376.86 | 23.13 | 0.31% |
| S&P/ASX 200 | 9,014.80 | 6.00 | -0.07% |
| SSE Composite Index | 3,669.46 | 20.28 | 0.56% |